Improvement of dry-weight in dialysis patients using bioelectrical impedance analysis
Completed
- Conditions
- Fluid overload dry-weight1008220610038430
- Registration Number
- NL-OMON36049
- Lead Sponsor
- Dianet, locatie AMC, Amsterdam
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 160
Inclusion Criteria
Patients must have CKD stage 5 and treatment with hemodialysis or peritoneal dialysis
Exclusion Criteria
Heart failure
Expected to receive a living donor transplant within 6 months
Life expectancy less than 6 months
Contraindications for the use of BIA measurements (due to expected measurement errors)
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>Blood pressure</p><br>
- Secondary Outcome Measures
Name Time Method <p>Number of hospital admissions due to fluid overload<br /><br>Number of additional dialysis sessions due to fluid overload<br /><br>Number of intradialytic hypotension episodes and/or the number<br /><br>hypotension-associated dialysis symptoms<br /><br>Number of antihypertensive drugs<br /><br>Serum levels of NT-proBNP, albumin and CRP<br /><br>Cardiovascular related morbidity and mortality<br /><br>Development of anuria (200 ml/day)</p><br>
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie bioelectrical impedance analysis (BIA) in optimizing dry-weight for dialysis patients with fluid overload?
How does BIA-guided dry-weight management compare to standard-of-care methods in reducing cardiovascular risks in fluid-overloaded dialysis patients?
Which biomarkers correlate with successful dry-weight adjustment using BIA in chronic kidney disease (CKD) patients on hemodialysis?
What adverse events are associated with BIA-based fluid overload monitoring in dialysis patients, and how are they managed?
Are there combination therapies or alternative technologies to BIA for improving dry-weight accuracy in dialysis populations?